Summary by Futu AI
On June 30, 2024, Aimai Vaccine released its interim report, which showed that the company achieved a revenue of approximately 537.2 million yuan during the period, a decrease of 0.6% compared to the same period in 2023. The company completed preclinical trial applications for 5 vaccine products and submitted clinical trial pre-applications for mRNA RSV vaccine and mRNA herpes zoster vaccine to the Drug Evaluation Center (CDE) of the National Medical Products Administration (NMPA), and also submitted relevant applications to the US FDA. The company actively explores the international market and promotes the entry of the lyophilized human rabies vaccine (Vero cell) and quadrivalent meningococcal vaccine into the international market. The net loss during the period was 145.3 million yuan, a decrease of 43.6% compared to the same period last year. As of the end of the reporting period, the company's net current liabilities amounted to 433.2 million yuan, an increase of 314.2 million yuan compared to the end of the previous year.
